Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.61 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.61 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.61 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21307901 | 0.91 | GUCY1B2 (0.61) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082095 | 0.90 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082443 | 0.81 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16081908 | 0.81 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082410 | 0.80 | GUCY1B2 (0.78) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL16082470 | 0.80 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Praliciguat SCHEMBL16082414 | 0.80 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| Praliciguat SCHEMBL29380287 | 0.80 | GUCY1B2 (0.74) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL25966818 | 0.80 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL25967108 | 0.80 | GUCY1B2 (0.77) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | disclosed |